ReviewBritish journal of clinical pharmacology2014
Future pharmacological treatments for substance use disorders.
Review in British journal of clinical pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 64 citations in OpenAlex.
- Carvedilol does not reduce cocaine use in methadone-maintained cocaine users.Journal of substance abuse treatment · 2017Trial
- Modafinil augments brain activation associated with reward anticipation in the nucleus accumbens.Psychopharmacology · 2014Trial
- Discriminative stimulus and locomotor activity profiles of nicotine and varenicline.Pharmacology, biochemistry, and behavior · 2026Article
- Association between venlafaxine use and the risk of withdrawal from nonopioid substances: a nationwide, population-based study.Harm reduction journal · 2026Article
- Corticotrophin-releasing hormone binding protein in the basolateral amygdala: divergent roles in cocaine and opioid addiction like behaviors.Addiction neuroscience · 2025Article
- Article
- A synergistic effect of herb and acupuncture on the methamphetamine.Integrative medicine research · 2024Article
- Amide naphthotube as a novel supramolecular sequestration agent for tetracaine and decamethonium.Theranostics · 2024Article
- Behavioral metabolomics: how behavioral data can guide metabolomics research on neuropsychiatric disorders.Metabolomics : Official journal of the Metabolomic Society · 2023Article
- Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report.International journal of environmental research and public health · 2022Article
- Carbonic Anhydrase Activators for Neurodegeneration: An Overview.Molecules (Basel, Switzerland) · 2022Review
- Reducing Addiction in Bipolar Disorder via Hacking the Dopaminergic System.Frontiers in psychiatry · 2021Review
- The vagus nerve mediates the suppressing effects of peripherally administered oxytocin on methamphetamine self-administration and seeking in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Article
- Supramolecular hosts as in vivo sequestration agents for pharmaceuticals and toxins.Chemical Society reviews · 2020Review
- Cocaine Administration and Its Abstinence Conditions Modulate Neuroglia.International journal of molecular sciences · 2020Article
- Substance use disorders: leading the road to recovery.RSC medicinal chemistry · 2020Review
- OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention.The Journal of pharmacology and experimental therapeutics · 2020Article
- Efficient Cocaine Degradation by Cocaine Esterase-Loaded Red Blood Cells.Frontiers in physiology · 2020Article
- The Relationship Between Serum Cytokine Levels and the Degree of Psychosis and Cognitive Impairment in Patients With Methamphetamine-Associated Psychosis in Chinese Patients.Frontiers in psychiatry · 2020Article
- Identification of cytotoxic markers in methamphetamine treated rat C6 astroglia-like cells.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Substance use disorders represent a serious public health and social issue worldwide. Recent advances in our understanding of the neurobiological basis of the addictive processes have led to the development of a growing number of pharmacological agents to treat addictions. Despite this progress, there are no approved pharmacological treatments for cocaine, methamphetamine and cannabis addiction. Moving treatment development to the next stage will require novel ways of approaching substance use disorders. One such novel approach is to target individual vulnerabilities, such as cognitive function, sex differences and psychiatric comorbidities. This review provides a summary of promising pharmacotherapies for alcohol, opiate, stimulant and nicotine addictions. Many medications that target positive and negative reinforcement of drugs, as well as individual vulnerabilities to addiction, are in different phases of development. Clinical trials testing the efficacy of these medications for substance use disorder are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.